Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 150 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... January 16, 2024 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ February 10, 2019 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Load more HOT NEWS FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival... What can elephants teach us about cancer? Woman Develops Breast Cancer After Double Mastectomy, Has to Have the...
